Identification of well-known biomarkers, e.g., estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), all of which are molecular targets of therapeutic agents, have achieved good outcomes in terms of survival and treatment of breast cancer patients. This evidence concerns the gene PGR and breast carcinoma.